// App-Quantinova.ai

: A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.

Researchers

Presenter

  • Masayuki Furukawa

Principal Investigators

  • Makoto Ueno

  • Daisuke Sakai

  • Kota Ouchi

  • Yasuo Hamamoto

  • Hiroshi Aikata

  • Masato Ozaka

  • Hidetaka Tsumura

  • Kunihiro Tsuji

  • Shoji Kubo

  • Tomohiro Nishina

  • Akio Katanuma

  • Chigusa Morizane

  • Masafumi Ikeda

  • Nobumasa Mizuno

  • Takashi Inagaki

  • Kazuhiko Shioji

  • Junji Furuse

Medical Centers

  • Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan

  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan

  • Department of Obstetrics and Gynecology, Tokai Univeresity Hospital, Kanagawa, Japan

  • Hyogo Cancer Center, Akashi, Japan

  • Osaka Metropolitan University, Osaka, Japan

  • Kanagawa Cancer Center, Yokohama, Japan

  • Osaka University Medical School, Suita, Japan

  • Niigata Cancer Center Hospital, Niigata City, Japan

  • National Cancer Center, EPOC, Chiba, Japan

  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

  • Division of outpatient chemotherapy, Cancer center, Keio University School of Medicine, Tokyo, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Chiba University Hospital, Chiba, Japan

  • Hiroshima University, Hiroshima-Shi, Japan

  • Kyushu Cancer Center, Fukuoka, Japan

  • National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

  • Dep. Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-Ward Tokyo, Japan

  • Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Gallbladder cancer

  • Ampullary carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved